Authors
Latest:
Median Lobe Urethral Embolus After Focal Ablation of Gleason 7 Prostate CancerThis is the case of a man, aged 56 years, who presented with urinary intermittency, frequency, urgency, and dysuria 5 months after undergoing focal laser ablation (FLA) of Gleason 3 + 4 = 7 prostate cancer (PC).
Latest:
67-year-old Male with Prostatic Stromal Tumor of Uncertain Malignant PotentialSTUMP: Elevated PSA, family history, risk factors, and clinical findings. What is the next step in this case? Experts weigh in.
Latest:
Biliary Cancer: Current Multimodality Treatment and Future DirectionsClinicians discuss appropriate evaluation and choice of management strategies for cholangiocarcinoma.
Latest:
Biliary Cancer: Current Multimodality Treatment and Future DirectionsClinicians discuss appropriate evaluation and choice of management strategies for cholangiocarcinoma.
Latest:
Therapy Options for Patients With Hepatocellular CarcinomaTherapy options for patients with hepatocellular carcinoma (HCC), including a newly approved therapy for a subpopulation of patient.
Latest:
Patient Survival Rates in High-Grade Spinal MeningiomaResearchers recently looked at differences in survival time between patients with grade II and grade III spinal meningioma.
Latest:
Metastasis-Directed Therapy in Prostate Cancer. Why, When, and How?Metastasis-directed therapy with stereotactic ablative radiotherapy has emerged as a promising complementary technique for the management of low-volume metastatic prostate cancer.
Latest:
Metastasis-Directed Therapy in Prostate Cancer. Why, When, and How?Metastasis-directed therapy with stereotactic ablative radiotherapy has emerged as a promising complementary technique for the management of low-volume metastatic prostate cancer.
Latest:
OncView™ Podcast: Updates in Managing Extensive-Stage Small Cell Lung CancerThis special edition of the “Oncology Peer Review On-The-Go” dives into recent updates and important treatment strategies for extensive-stage SCLC management.
Latest:
Classifying DLBCL Subtypes for Optimal TreatmentJennifer Crombie, MD, discusses classification of diffuse large B-cell lymphoma (DLBCL) into distinct subtypes and treatment decisions based on molecular classifications.
Latest:
Mutations and the Importance of Genetic TestingDr. Allison W. Kurian discusses a new breast cancer study that analyzed the mutations present in breast tumors, and about emerging targeted therapy options.
Latest:
Sonrotoclax/Zanubrutinib Combo Elicits Deep Responses for Untreated CLL/SLLFor patients with CLL and SLL, sonrotoclax with zanubrutinib yielded high rates of overall response in the phase 1/1b BGB-11417-101 study.
Latest:
42nd Annual Miami Breast Cancer Conference: The Show and After ShowCo-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Latest:
Sacituzumab Govitecan Combo Yields Early Activity in Metastatic NSCLCData from the phase 2 EVOKE-02 trial support further assessment of sacituzumab govitecan plus pembrolizumab as a frontline treatment for metastatic non–small cell lung cancer.
Latest:
Jason Williams, MD, on Intratumoral Immunotherapy Advances at SITC 2019Jason Williams, MD, discusses the development of intratumoral immunotherapy, as well as trial results from his poster presentation at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).
Latest:
Joshua Brody, MD, on Cross-Section of Science and Medicine at SITC 2019Joshua Brody, MD, discusses the gratification of the crossover between medicine and science at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).
Latest:
Experts Identify Steps to Improve Representation of African Americans in Multiple Myeloma Studies“The importance of diverse representation cannot be underscored enough and is critical to ensure that safe and effective products are available to the [United States] patient population,” wrote the study authors, who were led by Nicole Gormley, MD.
Latest:
Robert Ferris, MD, on Immunotherapy Transforming Cancer TreatmentRobert Ferris, MD, from UPMC Hillman Cancer Center, discusses the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019), and how immunotherapy will continue to transform cancer treatment.
Latest:
What Are the Most Common Esophageal MetastasesA rare occurrence, cancer in the esophagus requires an individualized treatment plan.
Latest:
KRAS+ NSCLC: Treatment Management StrategiesThis video segment discusses strategies for patient education and preparation for second-line treatment with RAS GTPase inhibitors, as well as therapeutic options to consider if a patient progresses on adagrasib.
Latest:
The Role of the Comprehensive Geriatric Assessment in the Evaluation of the Older Cancer PatientGeriatric assessments have now been recommended as part of the standard evaluation of an older adult considering cancer therapy.
Latest:
Polatuzumab Vedotin Regimen Yields ‘Meaningful’ Benefit in DLBCL, Expert SaysPolatuzumab vedotin-piiq plus R-CHP can reduce the need for any subsequent lines of therapy for patients with diffuse large B-cell lymphoma, according to an expert from The University of Texas MD Anderson Cancer Center.
Latest:
The Role of the Comprehensive Geriatric Assessment in the Evaluation of the Older Cancer PatientGeriatric assessments have now been recommended as part of the standard evaluation of an older adult considering cancer therapy.
Latest:
CLL14 Trial: Fixed-Duration Chemotherapy-Free Regimen for Frail Patients with Treatment-Naïve CLLThe treatment landscape for chronic lymphocytic leukemia has dramatically changed in the past decade.
Latest:
CLL14 Trial: Fixed-Duration Chemotherapy-Free Regimen for Frail Patients with Treatment-Naïve CLLThe treatment landscape for chronic lymphocytic leukemia has dramatically changed in the past decade.
Latest:
Domenico Mallardo, MD, on Anti-CTLA4 Agents in MelanomaDomenico Mallardo, MD, Istituto Nazionale Tumori "Fondazione Pascale" in Naples, discusses results from his trial – designed to evaluate anti-CTLA4 agents in patients with melanoma who relapsed on treatment with ipilimumab (Yervoy), which was presented at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).
Latest:
Luca Biavati, MD, on Bone Marrow T-Cells for Adoptive Cell TherapyLuca Biavati, MD, from Johns Hopkins Medicine, discussed bone marrow T-cells and bone marrow infiltrating lymphocytes as a source for adoptive cell therapy at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).
Latest:
What Are the Most Common Esophageal MetastasesA rare occurrence, cancer in the esophagus requires an individualized treatment plan.
Latest:
Marjorie Zauderer, MD, on New Immunotherapy ApproachesMarjorie Zauderer, MD, from Memorial Sloan Kettering Cancer Center, discussed new immunotherapy approaches at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).
